NEX2US Newsletter Issue 09 | March 2023

Topics

Awards and Recognition

  • HSA won five Public Service Transformation (PST) Awards 2021/2022

Regulatory Updates and Process Enhancements

  • Therapeutic Products (TP) - Enabling regulatory efficiency and industry self-help
  • Medical Devices (MD) -  Publication of Regulatory Guidelines for Laboratory Developed Tests (LDTs)
  • Complementary Health Products - Launch of Voluntary Notification System for Health Supplements and Traditional Medicines

International and Bilateral Collaborations

  • HSA Singapore the First National Regulatory Authority Awarded the Highest Recognition for an Advanced Medicines Regulatory System by the World Health Organization
  • Publication of the Access Consortium Statement on GMP Inspections Reliance and Recognition
  • Collaboration under the Access Consortium to enable faster access to treatment
  • ASEAN Pharmaceutical Regulatory Policy and ASEAN Pharmaceutical Regulatory Framework
  • HSA recognised by Australia’s Therapeutic Goods Administration (TGA) as a Comparable Overseas Regulator for medical devices
  • HSA included in Hong Kong’s list of reference countries for registration of new chemical or biological entity

News and Engagements

  • Complementary Health Products (CHP) Industry Training Workshop
  • Webinar on Dental Laboratory Regulatory Requirements in Singapore

Click on the link below to download the issue in pdf:

NEX2US Issue 091284 KB 
Industry member, Cell, Tissue and Gene Therapy Products, Chinese Proprietary Medicines, Controlled drugs, psychotropic substances and poisons, Cosmetic products, Health supplements, Homeopathic medicines, Medical devices, Therapeutic Products, Traditional medicines


Subscribeto stay up to date with HSA news and regulatory updates.

NEX2US Newsletters